<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141689">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256437</url>
  </required_header>
  <id_info>
    <org_study_id>6046</org_study_id>
    <nct_id>NCT01256437</nct_id>
  </id_info>
  <brief_title>Evaluating Preventive Therapy With Oint Threolone, Synthomycine or Aqua Cream Lotion, for EGFR'I Induced Acneiform Rash</brief_title>
  <acronym>EGFR'I</acronym>
  <official_title>Double Blind Placebo Controlled Trial, for Evaluating Preventive Therapy With Either Oint Threolone Versus Synthomycine Versus Aqua Cream Lotion, for EGFR'I Induced Acneiform Rash</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesized that topical anti-inflammatory treatment could counteract the
      inflammatory reaction induced by EGFR'Is.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients developing grade 2 / above rash under preventative treatment with ointment threolone, compared to the other 2 treatment arms.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients developing a rash under preventative treatment with ointment threolone, compared to the other 2 treatment arms</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Acneiform Rash</condition>
  <arm_group>
    <arm_group_label>ointment Threolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with topical application of combined anti inflammatory and anti bacterial agent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ointment Synthomycine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ointment once daily for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aqua cream lotion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Threolone ointment</intervention_name>
    <description>ointment once daily for 1 month</description>
    <arm_group_label>ointment Threolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ointment Synthomycine</intervention_name>
    <description>ointment once daily for 1 month</description>
    <arm_group_label>ointment Threolone</arm_group_label>
    <arm_group_label>ointment Synthomycine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aqua cream lotion</intervention_name>
    <description>ointment once daily for 1 month</description>
    <arm_group_label>ointment Threolone</arm_group_label>
    <arm_group_label>ointment Synthomycine</arm_group_label>
    <arm_group_label>Aqua cream lotion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are planed to initiate treatment with either cetuximab , erlotinib,
             gefitinib or panitumumab.

        Exclusion Criteria:

          -  Patients who received any facial topical treatment / systemic antibiotics or any
             anti-inflammatory drug during the 2 weeks prior to study initiation.

          -  Known hypersensitivity to ointment Synthomycine or to Threolone.

          -  Patients presented with cutaneous rash during the 2 weeks prior to study initiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Iris Amitay-Laish, MD</last_name>
    <phone>972-3-937-7160/3</phone>
    <email>amitay2@zahav.net.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salomon Stemmer, MD</last_name>
    <phone>972-3-937-7160/3</phone>
    <email>stemmer@post.tau.ac.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Davidoff Center, Rabin Medical Center, Beilinson</name>
      <address>
        <city>Petach Tikva,</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Amitay-Laish, MD</last_name>
      <phone>972-3-937-7160/3</phone>
      <email>amitay2@zahav.net.il</email>
    </contact>
    <investigator>
      <last_name>Iris Amitay-Laish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SALOMON STEMMER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Lee JE, Lee SJ, Lee HJ, Lee JH, Lee KH. Severe acneiform eruption induced by cetuximab (Erbitux). Yonsei Med J. 2008 Oct 31;49(5):851-2. doi: 10.3349/ymj.2008.49.5.851.</citation>
    <PMID>18972607</PMID>
  </reference>
  <reference>
    <citation>Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010 Mar 10;28(8):1351-7. doi: 10.1200/JCO.2008.21.7828. Epub 2010 Feb 8.</citation>
    <PMID>20142600</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 27, 2013</lastchanged_date>
  <firstreceived_date>December 7, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>iris amitay</investigator_full_name>
    <investigator_title>Iris Amitay-Laish, MD</investigator_title>
  </responsible_party>
  <keyword>Acneiform eruption</keyword>
  <keyword>papulopustular</keyword>
  <keyword>EGFR</keyword>
  <keyword>cetuximab</keyword>
  <keyword>erlotinib</keyword>
  <keyword>gefitinib</keyword>
  <keyword>panitumumab</keyword>
  <keyword>eruption secondary to treatment with either cetuximab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
